Ezabenlimab (BI 754091) and mDCF (Docetaxel, Cisplatin and 5-fluorouracil) Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma. A Phase II Study
Latest Information Update: 07 Aug 2024
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Ezabenlimab (Primary) ; Fluorouracil (Primary) ; Capecitabine; Mitomycin
- Indications Anal cancer; Carcinoma; Squamous cell cancer
- Focus Proof of concept; Registrational; Therapeutic Use
- Acronyms INTERACT-ION
- 20 Jan 2024 Preliminary results ( At analysis cut-off date,n=43 )presented at the 2024 Gastrointestinal Cancers Symposium
- 21 Dec 2023 Status changed from recruiting to active, no longer recruiting.
- 25 May 2023 Planned End Date changed from 5 Jul 2025 to 5 Jul 2026.